Form 4 for ARWR ARROWHEAD PHARMACEUTICALS, INC.
Accepted 2023-01-11 00:00:00 ET · period of report 2023-01-09 · accession 0001209191-23-003073 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-11 | 2023-01-09 | ARWR | Waddill William D. | Dir | S - Sale | $30.00 | -3,200 | 28.9K | -10% | -$96.0K |
| D | 2023-01-11 | 2023-01-10 | ARWR | Waddill William D. | Dir | A - Grant | $0.00 | +7,867 | 36.8K | +27% | $0 |
| D | 2023-01-11 | 2023-01-10 | ARWR | Waddill William D. | Dir | A - Grant | $0.00 | +4,593 | 4,593 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-09 | S | D | 3,200 | $30.00 | 28,950 | D | — | — | (F1) The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| 2 | Common | Common Stock | 2023-01-10 | A | A | 7,867 | $0.00 | 36,817 | D | — | — | (F2) Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary of the grant date. |
| 3 | Derivative | Common Stock | 2023-01-10 | A | A | 4,593 | $0.00 | 4,593 | D | $33.03 · 2024-01-10 to 2033-01-10 | 4,593 Common Stock | (F3) Represents options, which will vest in one installment on the first anniversary of the grant date. |